SHC (Sotera Health Co) Debt-to-EBITDA : 4.66 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sotera Health Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sotera Health Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $23 Mil. Sotera Health Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $2,328 Mil. Sotera Health Co's annualized EBITDA for the quarter that ended in Dec. 2024 was $505 Mil. Sotera Health Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 4.66.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sotera Health Co's Debt-to-EBITDA or its related term are showing as below:

SHC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -116.7 Med: 5.72 Max: 9.38
Current: 5.32

During the past 7 years, the highest Debt-to-EBITDA Ratio of Sotera Health Co was 9.38. The lowest was -116.70. And the median was 5.72.

SHC's Debt-to-EBITDA is ranked worse than
89.62% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.58 vs SHC: 5.32

Sotera Health Co Debt-to-EBITDA Historical Data

The historical data trend for Sotera Health Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sotera Health Co Debt-to-EBITDA Chart

Sotera Health Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-EBITDA

Get a 7-Day Free Trial

5.97

4.56

-116.70

5.72

5.32

Sotera Health Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-EBITDA	Get a 7-Day Free Trial															3.90	6.29	6.15	4.63	4.66

Competitive Comparison of Sotera Health Co's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Sotera Health Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sotera Health Co's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sotera Health Co's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Sotera Health Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sotera Health Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(22.782	+	2327.851)	/	442.202
	=	5.32

Sotera Health Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(22.782	+	2327.851)	/	504.944
	=	4.66

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.

Sotera Health Co (NAS:SHC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Sotera Health Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sotera Health Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Sotera Health Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sotera Health Co (NAS:SHC) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

9100 South Hills Boulevard, Suite 300, Broadview Heights, OH, USA, 44147

Website

https://www.soterahealth.com

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe and other regions.

Executives

Warburg Pincus & Co.	director, 10 percent owner	450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147
Gtcr Fund Xi/a Lp	director, 10 percent owner	300 NORTH LASALLE STREET, SUITE 5600, CHICAGO IL 60654
Ann R. Klee	director	30 ISABELLA ST., PITTSBURGH PA 15212
Michael P Rutz	officer: President of Sterigenics	8755 WEST HIGGINS ROAD, SUITE 500, CHICAGO IL 60631
Petras Michael B. Jr.	director, officer: Chairman & CEO	9100 SOUTH HILLS BLVD, SUITE 300, BROADVIEW HEIGHTS OH 44147
Jonathan M. Lyons	officer: Sr. Vice President, CFO	9100 SOUTH HILLS BLVD., SUITE 300, BROADVIEW HEIGHTS OH 44147
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Robert Brown Knauss	director	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Alexander Dimitrief	officer: SVP, General Counsel and Sec.	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Michael F Biehl	officer: Interim CFO	5885 LANDBROOK DRIVE SUITE 205, CLEVELAND OH 44124
Terry Hammons	officer: SVP, GC and Secretary	C/O SIMPSON MANUFACTURING CO., INC., 5956 W LAS POSITAS BLVD, PLEASANTON CA 94588
Wp Xi Partners, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, 450 LEXINGTON AVENUE NY 10017
Matthew J Klaben	officer: SVP, GC and Secretary	ONE INFINITY CORPORATE CENTRE DRIVE, SUITE 300, GARFIELD HEIGHTS OH 44125
Stephanie Geveda	director	450 LEXINGTON AVENUE, C/O WARBURG PINCUS LLC, NEW YORK NY 10017
Sean Laurence Cunningham	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654